For example, both pathologies commonly show mutations in the genes TP53 and CDKN2A. In addition to these shared alterations, PDAC frequently exhibits mutations in KRAS, as well as ERBB2 and SMAD4, whereas HCC is often characterized with mutations in the TERT promoter, CTNNB1 and AXIN-1. Here, ERBB2 is linked to hepatocellular carcinoma.